Spooked by Retail Zombies and Orphan Drugs

Update: 2017-02-16

Description

Orphan drugs are stirring up controversy over high prices and lavish incentives. Heard on the Street's Charley Grant discusses what might change. Then, Miriam Gottfried explains why there are so many zombie retailers these days and how they are hanging on financially.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Comments

In Channel

Banco Popular: Europe's Successful Failure

2017-06-0822:53

Adventures in Venezuela With Goldman Sachs

2017-06-0125:18

Drones Are Everywhere But Profits Elusive

2017-05-2520:08

Nvidia's Growth Is the Envy of Intel

2017-05-1822:44

Why Washington is Hammering Home Builders

2017-05-1124:53

How Big Can Facebook Get?

2017-05-0421:44

The Incredible Sinking Money Machine

2017-04-2720:06

Cloudy Skies for Goldman Sachs and Unicorns

2017-04-2018:51

United Debacle Is Just One Risk for Airlines

2017-04-1317:08

Are Car Sales Pointing to an Economic Pile Up?

2017-04-0619:24

Why China's Tencent is Tesla's Latest Fan

2017-03-3021:41

Why Wall Street Can't Bank on Trump Tax Cut

2017-03-2321:02

Trump's Immigration Rules and the Coming Food Price Pinch

2017-03-1620:51

Trumpcare Won't Make Health Insurers Sick

2017-03-0920:55

Snap IPO: What Comes Next?

2017-03-0224:19

Tesla Worries Aren't Going Away Anytime Soon

2017-02-2320:50

Spooked by Retail Zombies and Orphan Drugs

2017-02-1618:33

Trump, Twitter and Well-Behaved Companies

2017-02-0922:05

Trump's New Rules Will Shake Up Global Banking

2017-02-0322:43

Will Apple's Next iPhone Be New Enough?

2017-02-0219:14

00:00

Spooked by Retail Zombies and Orphan Drugs

Miriam Gottfried and Alex Frangos

#box-pro-ellipsis-175724439782519{-webkit-line-clamp:2;}Spooked by Retail Zombies and Orphan Drugs

Spooked by Retail Zombies and Orphan Drugs

Miriam Gottfried and Alex Frangos

Spooked by Retail Zombies and Orphan Drugs